BJH - volume 11, issue 8, december 2020
M.C. Vekemans MD, C. Doyen MD, K.L. Wu MD, PhD, A. Kentos MD, PhD, P. Mineur MD, L. Michaux MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, M. Delforge MD, PhD, On behalf of the BHS Myeloma Subgroup
With the introduction of immunomodulatory drugs, proteasome inhibitors and anti-CD38 monoclonal anti-bodies, major improvements have been achieved in the treatment and outcome of multiple myeloma (MM). Different treatment combinations are now in use and other therapies are being developed. This rapidly changing therapeutic landscape urges for an update on practical guidelines. Based on an extensive review of the recent literature, we propose recommendations on myeloma management, to be used by haematologists as a reference for daily practice.
(BELG J HEMATOL 2020;11(8):357-75)
Read moreBJH - volume 11, issue 7, november 2020
M.C. Vekemans MD, C. Doyen MD, K.L. Wu MD, PhD, A. Kentos MD, PhD, P. Mineur MD, L. Michaux MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, M. Delforge MD, PhD, On behalf of the BHS Myeloma Subgroup
With the introduction of immunomodulatory drugs, proteasome inhibitors and anti-CD38 monoclonal antibodies, major improvements have been achieved in the treatment and outcome of multiple myeloma (MM). Different treatment combinations are now in use and other therapies are being developed. This rapidly changing therapeutic landscape urges for an update on practical guidelines. Based on an extensive review of the recent literature, we propose recommendations on myeloma management, to be used by haematologists as a reference for daily practice.
(BELG J HEMATOL 2020;11(7):286-304)
Read moreBJH - volume 10, issue 3, may 2019
N. Meuleman MD, PhD, C. Doyen MD, K.L. Wu MD, PhD, P. Mineur MD, G. Bries MD, PhD, A. Kentos MD, PhD, L. Michaux MD, PhD, M. Delforge MD, PhD
With the introduction of immunomodulatory agents and proteasome inhibitors, major improvements have been achieved in the treatment and outcome of multiple myeloma. Different treatment combinations are now in use and newer therapies are being developed. Nevertheless, autologous stem cell transplantation remains the corner stone of therapy for fit, newly-diagnosed multiple myeloma patients. Based on an extensive review of the recent literature, we propose recommendations on myeloma care, to be used by haematologists as a reference for daily practice.
(BELG J HEMATOL 2019;10(3):113–21)
Read moreBJH - volume 9, issue Multiple Myeloma Special Edition, december 2018
N. Meuleman MD, PhD, C. Doyen MD, K.L. Wu MD, PhD, P. Mineur MD, G. Bries MD, PhD, A. Kentos MD, PhD, L. Michaux MD, PhD, M. Delforge MD, PhD
With the introduction of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs), major improvements have been achieved in the treatment and outcome of multiple myeloma (MM). Different treatment combinations are now in use and newer therapies are being developed. Nevertheless, autologous stem cell transplantation (ASCT) remains the corner stone of therapy for fit, newly-diagnosed MM patients. Based on an extensive review of the recent literature, we propose recommendations on myeloma care, to be used by haematologists as a reference for daily practice.
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
B. Stamatopoulos , T. Smith , E. Crompot , K. Pieters , R. Clifford , M. Mraz , P. Robbe , A. Burns , A. Timbs , D. Bruce , P. Hillmen , N. Meuleman MD, PhD, P. Mineur MD, R. Firescu , M. Maerevoet MD, V. De Wilde MD, PhD, A. Efira MD, J. Philippé MD, PhD, B. Verhasselt MD, PhD, F. Offner MD, PhD, A. Heger , D. Sims , H. Dreau , A. Schuh
BJH - volume 8, issue 2, march 2017
M.C. Vekemans MD, K. Beel MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, G. Bries MD, PhD, H. Demuynck MD, B. De Prijck MD, H. De Samblanx MD, A. Deweweire MD, K. Fostier MD, A. Kentos MD, PhD, P. Mineur MD, M. Vaes MD, I. Vande Broek MD, PhD, A. Vande Velde MD, J. Van Droogenbroeck MD, P. Vlummens MD, K.L. Wu MD, PhD, R. Schots MD, PhD, M. Delforge MD, PhD, C. Doyen MD, On behalf of the Multiple Myeloma Study Group of the Belgian Haematology Society (BHS)
The prognosis for multiple myeloma patients has improved substantially over the past decade with the development of more effective chemotherapeutic agents and regimens that possess a high level of anti-tumour activity. However, nearly all multiple myeloma patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed disease remains a critical aspect of multiple myeloma care and an important area of ongoing research. This manuscript from the Belgian Haematology Society multiple myeloma subgroup provides some recommendations on the management of relapsed disease.
(BELG J HEMATOL 2017;8(2):53–65)
Read moreBJH - volume 8, issue Abstract Book BHS, february 2017
Q. Delefortrie , F. Lambert MD, G. Bulliard , M. Jurdan , S. Toffoli PhD, MSc, D. Sartenaer , S. De Prophetis , D. Pranger MD, A. Kornreich MD, P. Mineur MD
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
